FDA knocks Lupin plant with warning letter after drugmaker failed to remedy operational woes

FDA Building 2
Lupin was hit with a second warning letter in three years by the FDA. (FDA)

Months after the FDA demanded Lupin act on failures at its Mandideep, India finished dose plant, the Indian drugmaker was waiting for the other shoe to fall. It fell in a form of a warning letter.

Lupin was hit with the warning letter after an “earlier intimation” from the FDA in March requiring Lupin to address a smorgasbord of manufacturing and data safety concerns, the company said in a regulatory filing (PDF) with the Bombay Stock Exchange.

The drugmaker said its Mandideep facility had no outstanding drug applications and did not expect that the letter would “have an impact on disruption of supplies or the existing revenues from operations of this facility.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The newest knock from the FDA followed a December investigation and damning Form 483. In that report, the agency cited a raft of failures at the Mandideep Unit 1 facility, including 11 observations in the API portion of the plant and another eight in finished dose operations.

 RELATED: FDA drops decisional letter on Lupin sterile drug operations

The plant’s many API problems included failing to adequately monitor environmental conditions and disinfect during media fills, to a general lack of knowledge among workers on what their day-to-day tasks were. Investigators said workers couldn’t automatically answer routine questions presented by FDA inspectors, and managers often had to read directly from manuals to explain their responsibilities.

In finished dose operations, Lupin received a swath of customer complaints, including a pediatric drug that customers found was thickening, making it difficult to dose. Some complaints said vials were short of the dose. The FDA said the plant’s quality control people didn’t put two-and-two together to investigate whether the thickening was the reason vials were short.

RELATED: FDA warning blasts Lupin for failing to learn from past mistakes

Of course, Lupin isn’t a first-time offender in the FDA’s eyes.

In November 2017, Lupin received a warning letter after the FDA found issues with key finished products plant in Goa and a plant in Indore, India. That letter said Lupin’s efforts to make improvements had fallen short and recommended it get a consultant to not only help fix those plants but to assess its entire manufacturing network.

The major concerns at that time focused on product testing. The FDA ordered Lupin to retest batches of drugs that the company had released for sale in the U.S. even though repeated testing found they failed to meet spec. At Lupin’s plant in Indore, analysts ignored nearly all of the initial out-of-spec testing results, 134 of 139 in a two-year period, the FDA said.

Suggested Articles

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung…